Brain Cancer
Temferon Is a Viable Treatment Option in Newly Diagnosed Glioblastoma
April 16, 2022
Article
Preliminary findings from the phase 1/2a TEM-GBM study highlight the potential utility of temferon, genetically modified Tie2-expressing monocytes targeting interferon a2 in treating patients with glioblastoma.
Adjuvant Neratinib Does Not Improve Overall Survival in Glioblastoma, Yet May Offer Benefit for EGFR+ Subset
March 10, 2022
Article
Although adjuvant neratinib was not found to improve progression-free or overall survival across a population of patients with glioblastoma, the agent yielded promising progression-free survival rates in a subset of patients with EGFR-positive disease.
Telehealth Program Supports Family Caregivers of Patients With Brain Cancer
April 09, 2021
Article
Caregivers have their own set of issues and anxieties, but a telehealth support service may help.
FDA OKs Berubicin for GBM Treatment
December 22, 2020
Article
The FDA has approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme.
AV-GBM-1 Vaccine Improves Glioblastoma Outcomes
November 18, 2020
Article
AV-GBM-1, a personalized cancer vaccine, demonstrated an improvement in progression-free survival (PFS) in patients with newly diagnosed glioblastoma, according to data from a phase 2 trial (NCT03400917).
FDA Grants Fast Track Status to Paxalisib for GBM Treatment
August 21, 2020
Article
The FDA has granted a fast track designation to paxalisib for the treatment of patients with glioblastoma.
FDA Grants Fast Track Status to Enzastaurin to Treat Newly Diagnosed GBM
July 23, 2020
Article
The FDA has granted a fast track designation for the PKCβ inhibitor enzastaurin for the treatment of patients with newly diagnosed glioblastoma.
FDA Accepts BLA for Bevacizumab Biosimilar
March 06, 2020
Article
The FDA has accepted a biologics license application for a proposed biosimilar for bevacizumab (Avastin), according to an announcement by Mylan during its fourth quarter 2019 earnings call.
Checkpoint Blockade Plus Vaccines Show Synergy in Early GBM Trials
December 06, 2019
Article
Glioblastoma is historically difficult to treat, but recent research shows some potential for immunotherapy/vaccine combinations for these patients.
New Agents Show Promise in Treating Patients with IDH1-Mutant Low-Grade Glioma
November 26, 2019
Article
Two new single agents led to brain penetrance and 2-hydroxyglutarate (2-HG) suppression in patients with low-grade glioma who harbor IDH1 mutations, according to updated findings.